[DISCLOSURE] Access Bio (950130) announced on Sept. 1 that it has signed a contract worth 2.9 billion won (US$2.6 million) with Partnership for Supply Chain Management in US, to supply malaria rapid diagnostic test (RDT).

The deal amounts to 8.1 percent of its revenue in 2015 and expires Jan. 9, 2017.

By Jung Min-kyung ()